The size of the APAC HIV Therapeutics Market was worth USD 2.33 billion in 2019 and estimated to be growing at a CAGR of 2.1%, to reach USD 2.59 billion by 2024.
The human immunodeficiency virus (HIV) refers to a kind of retrovirus that causes (AIDS). HIV affects some immune cells and it weakens the immune system bringing about loss of capacity to fight against the organisms that cause diseases.
HIV infection has no cure however there are medicines that help to balance out or decrease this infection so it doesn't prompt AIDS. HIV therapeutics market is developing at a significant rate because of increment in the HIV infected cases and developing awareness about the same.
Major Driving factors are the increasing number of HIV affected cases, an innovative advancement in HIV diagnosis and therapeutics, ascend in research exercises for developing HIV immunizations and not aware of the methods of transmission of the infection. Moreover, increasing awareness about the accessibility of HIV therapeutics in the market and cost-effective sedate treatments for HIV are driving the Asia Pacific HIV Therapeutics Market.
Be that as it may, different variables, for example, the disappointment of treatment sometimes, absence of gifted experts and presentation of non-specific medications in the market are major restraints the Asia Pacific HIV Therapeutics Market.
This research report is segmented &b sub-segmented the market into the following categories:
Regionally, the Asian, African and South American areas are developing markets as of now contributing under 20% partake in the worldwide HIV market. The current development of the market in the Asia Pacific is, however, a positive sign for potential makers, with whatever remains of the world after a comparable example. The Asia Pacific is anticipated to be the fastest developing regional section and will hold its position over the forecast period inferable from the upgrading medicinal services foundation and presence of appropriate government activities favoring development.
Companies playing a key role in the APAC HIV Therapeutics Market profiled in this report are GlaxoSmithKline, Bristol-Myers Squibb, Pfizer, Boehringer Ingelheim, Merck, Hoffmann-La Roche and Gilead Sciences.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Drug Class
5.1.1 Introduction
5.1.2 integrase inhibitor
5.1.3 nucleoside/nucleotide reverse transcriptase inhibitor
5.1.4 non-nucleoside turn around transcriptase inhibitor
5.1.5 HIV-1 protease inhibitor
5.1.6 pharmacokinetic enhancer
5.1.7 passage inhibitor
5.1.8 Y-o-Y Growth Analysis, Drug class
5.1.9 Market Attractiveness Analysis, Drug class
5.1.10 Market Share Analysis, Drug class
5.2 Application
5.2.1 Introduction
5.2.2 HIV Type-1
5.2.3 HIV Type-2
5.2.4 Y-o-Y Growth Analysis, Application
5.2.5 Market Attractiveness Analysis, Application
5.2.6 Market Share Analysis, Application
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 Drug Class
6.1.3.3 HIV TYPE 1&2
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 Drug Class
6.1.4.3 HIV TYPE 1&2
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 Drug Class
6.1.5.3 HIV TYPE 1&2
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Athersys
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 StemCells
8.3 Cryo Cell International
8.4 Geron Corporation
8.5 Mesoblast
8.6 Aastrom Biosciences
8.7 Celgene Corporation
8.8 Invitrogen
8.9 Cytori Therapeutics
8.10 Retractable Technologies
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
